- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.90 Å
- Oligo State
- hetero-6-6-6-6-mer
- Ligands
- 6 x GLY- SER- SER- SER- THR: POLIOVIRUS TYPE 1 MAHONEY(Non-covalent)
- 6 x J78: (METHYLPYRIDAZINE PIPERIDINE PROPYLOXYPHENYL)ETHYLACETATE(Non-covalent)
J78.2: 17 residues within 4Å:- Chain A: I.110, T.111, Y.112, M.132, L.134, I.157, Y.159, P.181, S.182, I.183, I.194, V.196, V.199, Y.205, F.237, L.240
- Chain C: A.24
13 PLIP interactions:12 interactions with chain A, 1 interactions with chain C- Hydrophobic interactions: A:I.110, A:Y.112, A:Y.159, A:Y.159, A:Y.159, A:P.181, A:I.183, A:I.194, A:V.199, A:F.237, C:A.24
- pi-Stacking: A:Y.205, A:F.237
J78.5: 17 residues within 4Å:- Chain E: I.110, T.111, Y.112, M.132, L.134, I.157, Y.159, P.181, S.182, I.183, I.194, V.196, V.199, Y.205, F.237, L.240
- Chain G: A.24
13 PLIP interactions:12 interactions with chain E, 1 interactions with chain G- Hydrophobic interactions: E:I.110, E:Y.112, E:Y.159, E:Y.159, E:Y.159, E:P.181, E:I.183, E:I.194, E:V.199, E:F.237, G:A.24
- pi-Stacking: E:Y.205, E:F.237
J78.8: 17 residues within 4Å:- Chain I: I.110, T.111, Y.112, M.132, L.134, I.157, Y.159, P.181, S.182, I.183, I.194, V.196, V.199, Y.205, F.237, L.240
- Chain K: A.24
13 PLIP interactions:12 interactions with chain I, 1 interactions with chain K- Hydrophobic interactions: I:I.110, I:Y.112, I:Y.159, I:Y.159, I:Y.159, I:P.181, I:I.183, I:I.194, I:V.199, I:F.237, K:A.24
- pi-Stacking: I:Y.205, I:F.237
J78.11: 17 residues within 4Å:- Chain M: I.110, T.111, Y.112, M.132, L.134, I.157, Y.159, P.181, S.182, I.183, I.194, V.196, V.199, Y.205, F.237, L.240
- Chain O: A.24
13 PLIP interactions:12 interactions with chain M, 1 interactions with chain O- Hydrophobic interactions: M:I.110, M:Y.112, M:Y.159, M:Y.159, M:Y.159, M:P.181, M:I.183, M:I.194, M:V.199, M:F.237, O:A.24
- pi-Stacking: M:Y.205, M:F.237
J78.14: 17 residues within 4Å:- Chain Q: I.110, T.111, Y.112, M.132, L.134, I.157, Y.159, P.181, S.182, I.183, I.194, V.196, V.199, Y.205, F.237, L.240
- Chain S: A.24
13 PLIP interactions:12 interactions with chain Q, 1 interactions with chain S- Hydrophobic interactions: Q:I.110, Q:Y.112, Q:Y.159, Q:Y.159, Q:Y.159, Q:P.181, Q:I.183, Q:I.194, Q:V.199, Q:F.237, S:A.24
- pi-Stacking: Q:Y.205, Q:F.237
J78.17: 17 residues within 4Å:- Chain U: I.110, T.111, Y.112, M.132, L.134, I.157, Y.159, P.181, S.182, I.183, I.194, V.196, V.199, Y.205, F.237, L.240
- Chain W: A.24
13 PLIP interactions:12 interactions with chain U, 1 interactions with chain W- Hydrophobic interactions: U:I.110, U:Y.112, U:Y.159, U:Y.159, U:Y.159, U:P.181, U:I.183, U:I.194, U:V.199, U:F.237, W:A.24
- pi-Stacking: U:Y.205, U:F.237
- 6 x MYR: MYRISTIC ACID(Covalent)
MYR.3: 10 residues within 4Å:- Chain D: G.1, A.2, I.29, Y.31
- Chain H: V.4, T.27, T.28, I.29, Y.31
- Ligands: GLY-SER-SER-SER-THR.4
4 PLIP interactions:2 interactions with chain D, 2 interactions with chain H- Hydrophobic interactions: D:I.29, D:Y.31, H:I.29
- Hydrogen bonds: H:T.27
MYR.6: 4 residues within 4Å:- Chain H: G.1, A.2, I.29, Y.31
2 PLIP interactions:2 interactions with chain H- Hydrophobic interactions: H:I.29, H:Y.31
MYR.9: 4 residues within 4Å:- Chain L: G.1, A.2, I.29, Y.31
2 PLIP interactions:2 interactions with chain L- Hydrophobic interactions: L:I.29, L:Y.31
MYR.12: 10 residues within 4Å:- Chain L: V.4, T.27, T.28, I.29, Y.31
- Chain P: G.1, A.2, I.29, Y.31
- Ligands: GLY-SER-SER-SER-THR.7
4 PLIP interactions:2 interactions with chain L, 2 interactions with chain P- Hydrophobic interactions: L:I.29, P:I.29, P:Y.31
- Hydrogen bonds: L:T.27
MYR.15: 10 residues within 4Å:- Chain T: G.1, A.2, I.29, Y.31
- Chain X: V.4, T.27, T.28, I.29, Y.31
- Ligands: GLY-SER-SER-SER-THR.16
4 PLIP interactions:2 interactions with chain X, 2 interactions with chain T- Hydrophobic interactions: X:I.29, T:I.29, T:Y.31
- Hydrogen bonds: X:T.27
MYR.18: 4 residues within 4Å:- Chain X: G.1, A.2, I.29, Y.31
2 PLIP interactions:2 interactions with chain X- Hydrophobic interactions: X:I.29, X:Y.31
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Grant, R.A. et al., Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr.Biol. (1994)
- Release Date
- 1996-07-11
- Peptides
- POLIOVIRUS TYPE 1 MAHONEY: AEIMQU
POLIOVIRUS TYPE 1 MAHONEY: BFJNRV
POLIOVIRUS TYPE 1 MAHONEY: CGKOSW
POLIOVIRUS TYPE 1 MAHONEY: DHLPTX - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
1E
1I
1M
1Q
1U
1B
2F
2J
2N
2R
2V
2C
3G
3K
3O
3S
3W
3D
4H
4L
4P
4T
4X
4
SMTL ID : 1vbd.3 (3 other biounits)
POLIOVIRUS (TYPE 1, MAHONEY STRAIN) COMPLEXED WITH R78206
POLIOVIRUS TYPE 1 MAHONEY
Toggle Identical (AEIMQU)POLIOVIRUS TYPE 1 MAHONEY
Toggle Identical (BFJNRV)POLIOVIRUS TYPE 1 MAHONEY
Toggle Identical (CGKOSW)POLIOVIRUS TYPE 1 MAHONEY
Toggle Identical (DHLPTX)Related Entries With Identical Sequence
1al2.1 | 1al2.2 | 1al2.3 | 1al2.4 | 1ar6.1 | 1ar6.2 | 1ar6.3 | 1ar6.4 | 1ar7.1 | 1ar7.2 | 1ar7.3 | 1ar7.4 | 1ar8.1 | 1ar8.2 | 1ar8.3 | 1ar8.4 | 1ar9.1 | 1ar9.2 | 1ar9.3 | 1ar9.4 | 1asj.1 | 1asj.2 | 1asj.3 | 1asj.4 | 1hxs.1 | 1hxs.2 | 1hxs.3 | 1hxs.4 | 1po1.1 | 1po1.2 more...less...1po1.3 | 1po1.4 | 1po2.1 | 1po2.2 | 1po2.3 | 1po2.4 | 1pov.1 | 1pov.2 | 1pov.3 | 1pov.4 | 1vbd.1 | 1vbd.2 | 1vbd.4 | 2plv.1 | 2plv.2 | 2plv.3 | 2plv.4 | 3epc.1 | 3epc.2 | 3epc.3 | 3epc.4 | 3j8f.1 | 3j8f.2 | 3j8f.3 | 3j8f.4 | 3j9f.1 | 3j9f.2 | 3j9f.3 | 3j9f.4 | 3jbc.1 | 3jbc.2 | 3jbc.3 | 3jbc.4 | 3jbd.1 | 3jbd.2 | 3jbd.3 | 3jbd.4 | 3jbe.1 | 3jbe.2 | 3jbe.3 | 3jbe.4 | 3jbf.1 | 3jbf.2 | 3jbf.3 | 3jbf.4 | 3jbg.1 | 3jbg.2 | 3jbg.3 | 3jbg.4 | 6p9o.1 | 6p9o.2 | 6p9o.3 | 6p9o.4 | 6p9w.1 | 6p9w.2 | 6p9w.3 | 6p9w.4 | 6psz.1 | 6psz.2 | 6psz.3 | 6psz.4 | 6q0b.1 | 6q0b.2 | 6q0b.3 | 6q0b.4 | 8e8l.1 | 8e8l.2 | 8e8l.3 | 8e8l.4